Cargando…

Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up

Objectives: This is a longitudinal prospective study which was designed to assess the trend of anti-SARS-CoV-2 antibodies targeting the Spike (anti-S) and Nucleocapside protein (anti-N) viral antigens over a 9-month period after the administration of an anti-SARS-CoV-2 vaccine in a big COVID-19 hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Sansone, Emanuele, Bonfanti, Carlo, Sala, Emma, Renzetti, Stefano, Terlenghi, Luigina, Matteelli, Alberto, Tiraboschi, Mara Maria, Pedrazzi, Tatiana, Lombardo, Massimo, Rossi, Camillo, Indelicato, Anna Maria, Caruso, Arnaldo, De Palma, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864433/
https://www.ncbi.nlm.nih.gov/pubmed/36679853
http://dx.doi.org/10.3390/vaccines11010008
_version_ 1784875583341068288
author Sansone, Emanuele
Bonfanti, Carlo
Sala, Emma
Renzetti, Stefano
Terlenghi, Luigina
Matteelli, Alberto
Tiraboschi, Mara Maria
Pedrazzi, Tatiana
Lombardo, Massimo
Rossi, Camillo
Indelicato, Anna Maria
Caruso, Arnaldo
De Palma, Giuseppe
author_facet Sansone, Emanuele
Bonfanti, Carlo
Sala, Emma
Renzetti, Stefano
Terlenghi, Luigina
Matteelli, Alberto
Tiraboschi, Mara Maria
Pedrazzi, Tatiana
Lombardo, Massimo
Rossi, Camillo
Indelicato, Anna Maria
Caruso, Arnaldo
De Palma, Giuseppe
author_sort Sansone, Emanuele
collection PubMed
description Objectives: This is a longitudinal prospective study which was designed to assess the trend of anti-SARS-CoV-2 antibodies targeting the Spike (anti-S) and Nucleocapside protein (anti-N) viral antigens over a 9-month period after the administration of an anti-SARS-CoV-2 vaccine in a big COVID-19 hospital located in Northern Italy. Participants: 7411 vaccinated workers were included in a linear mixed-effect model analysis performed to model the anti-S decay over the 9 months following the vaccination, during serological screening performed approximately 2, 4, and 9 months following the first jab administration. Serological tests performed in the 9 months preceding vaccine administration were retrospectively analysed to identify the burden of infections occurring before vaccination. Results: The serological assays were used for monitoring the antibody titres during the observational period. Vaccination significantly reduced the rate of infection and elicited a specific humoral response, which lasted during the whole observational period (9 months). A decay was observed in all considered subgroups. At 35 weeks, workers with no history of pre-vaccine infection showed a significantly lower anti-S titre (−2522 U/mL on average (−2589.7 to −2445.7)); younger workers showed significantly higher anti-S titres (140.2 U/mL on average (82.4 to 201.3)). Only seven immunocompromised workers did not show significant levels of anti-S antibodies; three of them, all females, showed a specific T-cell response. Conclusions: Comparing the 9-month periods before and after the first vaccine dose, a significant reduction in infection rate was observed (1708 cases vs. 156). Pre-vaccine infection, especially if contracted during the first pandemic wave, greatly enhanced the response to vaccination, which was significantly affected also by age both in extent and duration (inversely related). A gender effect on the T-cell immune response was observed in a small group of workers who did not produce antibodies after vaccine administration.
format Online
Article
Text
id pubmed-9864433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98644332023-01-22 Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up Sansone, Emanuele Bonfanti, Carlo Sala, Emma Renzetti, Stefano Terlenghi, Luigina Matteelli, Alberto Tiraboschi, Mara Maria Pedrazzi, Tatiana Lombardo, Massimo Rossi, Camillo Indelicato, Anna Maria Caruso, Arnaldo De Palma, Giuseppe Vaccines (Basel) Article Objectives: This is a longitudinal prospective study which was designed to assess the trend of anti-SARS-CoV-2 antibodies targeting the Spike (anti-S) and Nucleocapside protein (anti-N) viral antigens over a 9-month period after the administration of an anti-SARS-CoV-2 vaccine in a big COVID-19 hospital located in Northern Italy. Participants: 7411 vaccinated workers were included in a linear mixed-effect model analysis performed to model the anti-S decay over the 9 months following the vaccination, during serological screening performed approximately 2, 4, and 9 months following the first jab administration. Serological tests performed in the 9 months preceding vaccine administration were retrospectively analysed to identify the burden of infections occurring before vaccination. Results: The serological assays were used for monitoring the antibody titres during the observational period. Vaccination significantly reduced the rate of infection and elicited a specific humoral response, which lasted during the whole observational period (9 months). A decay was observed in all considered subgroups. At 35 weeks, workers with no history of pre-vaccine infection showed a significantly lower anti-S titre (−2522 U/mL on average (−2589.7 to −2445.7)); younger workers showed significantly higher anti-S titres (140.2 U/mL on average (82.4 to 201.3)). Only seven immunocompromised workers did not show significant levels of anti-S antibodies; three of them, all females, showed a specific T-cell response. Conclusions: Comparing the 9-month periods before and after the first vaccine dose, a significant reduction in infection rate was observed (1708 cases vs. 156). Pre-vaccine infection, especially if contracted during the first pandemic wave, greatly enhanced the response to vaccination, which was significantly affected also by age both in extent and duration (inversely related). A gender effect on the T-cell immune response was observed in a small group of workers who did not produce antibodies after vaccine administration. MDPI 2022-12-20 /pmc/articles/PMC9864433/ /pubmed/36679853 http://dx.doi.org/10.3390/vaccines11010008 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sansone, Emanuele
Bonfanti, Carlo
Sala, Emma
Renzetti, Stefano
Terlenghi, Luigina
Matteelli, Alberto
Tiraboschi, Mara Maria
Pedrazzi, Tatiana
Lombardo, Massimo
Rossi, Camillo
Indelicato, Anna Maria
Caruso, Arnaldo
De Palma, Giuseppe
Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up
title Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up
title_full Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up
title_fullStr Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up
title_full_unstemmed Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up
title_short Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up
title_sort immune responses to sars-cov-2 infection and vaccine in a big italian covid-19 hospital: an 18-month follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864433/
https://www.ncbi.nlm.nih.gov/pubmed/36679853
http://dx.doi.org/10.3390/vaccines11010008
work_keys_str_mv AT sansoneemanuele immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT bonfanticarlo immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT salaemma immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT renzettistefano immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT terlenghiluigina immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT matteellialberto immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT tiraboschimaramaria immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT pedrazzitatiana immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT lombardomassimo immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT rossicamillo immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT indelicatoannamaria immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT carusoarnaldo immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup
AT depalmagiuseppe immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup